By Mark Chael --
Meridian Biosciences, Inc. (Nasdaq: VIVO) of Cincinnati, OH recently announced that its subsidiary, Meridian Life Sciences, Inc., has manufactured an infectious inoculum of respiratory syncytial virus (RSV) to be used in human challenge studies of healthy volunteers. RSV is an enveloped RNA virus and the most common cause of pneumonia and bronchitis in infants. The challenge studies are to be conducted by Alnylam Pharmaceuticals (Nasdaq: ALNY) of Cambridge, MA. These studies will establish optimal infectious levels of the RSV inoculum as a prelude to testing Alnylam's RNAi therapeutic compound, ALN-RSV01.
Comments